We’re so glad you’re here, Oscar Velastegui, Aaron Ilan, Ph.D., Quyen Nguyen, Khalil Saikali, Nghi Nguyen, and Matthew Habermehl! #WeAreAnaptysBio Today marks the official spin-off of First Tracks Biotherapeutics, a clinical stage biotech developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory... Search our free database to find email addresses and direct dials for AnaptysBio employees. Effective April 20, 2026, Anaptys has spun off its biopharma business, including its therapies, into a new company, First Tracks Biotherapeutics. He has served as Anaptys’ president and chief executive officer since March 2022. Previously, he was chief operating officer at Mirati Therapeutics responsible for leading the company’s corporate strategy, finance, legal and other business operations. AnaptysBio, founded in 2005 and headquartered in California, is a clinical-stage biotechnology company focused on developing novel antibody therapeutics. The company specializes in creating treatments for inflammatory diseases and immuno-oncology indications. Explore AnaptysBio's employee directory to find accurate email addresses and contact information. Book a demo today. For the first time in my career, I've decided to re-join the values-driven team at Cytokinetics as Vice President, Clinical Operations and Research Ethics. Description: Filed by "insiders" prior intended sale of restricted stock. Data provided by Kaleidoscope. The Investor Relations website contains information about AnaptysBio, Inc.'s business for stockholders, potential investors, and financial analysts.